Blinatumomab is a drug approved by the US Food and Drug Administration to treat B-precursor acute lymphoblastic leukemia. Blinatumomab is given by daily infusion for 28 days per cycle. The first few infusions of Cycles 1 and 2 are given in the hospital. The purpose of this study is to see if Blinatumomab can be given at home safely for the entire 28-day cycle.
The purpose of this study is to learn more about the study drug ABBV-383 in patients with amyloidosis. We want to find the best dose and learn about the safety and effects of the study drug.
The purpose of this study is to find out if the study drug, Inotuzumab Ozogamicin, can help treat certain types of leukemia. The study drug will be given along with the usual chemotherapy.
The purpose of this study is to find out if the study drugs, Inotuzumab Ozogamicin and Blinatumomab, can improve the chance of your leukemia going away. We also want to find out if we the study drugs can lower the chance of your leukemia coming back. We want to find out if this approach is better or worse than the usual approach.
Lymphoblastic Leukemia (B-ALL) is a cancer of the white blood cells. The purpose of this study is to find out how well the study drug, Inotuzumab ozogamicin, works for children and young adults with B-ALL.
